Cargando…

The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) present subclinical left ventricular systolic and/or diastolic dysfunction (LVD). Dipeptidyl peptidase-4 (DPP4) inactivates peptides that possess cardioprotective actions. Our aim was to analyze whether the activity of circulating DPP4 is ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ravassa, Susana, Barba, Joaquín, Coma-Canella, Isabel, Huerta, Ana, López, Begoña, González, Arantxa, Díez, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852480/ https://www.ncbi.nlm.nih.gov/pubmed/24099410 http://dx.doi.org/10.1186/1475-2840-12-143

Ejemplares similares

Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population
por: Cauwenberghs, Nicholas, et al.
Publicado: (2019)

Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus
por: Mochizuki, Yasuhide, et al.
Publicado: (2015)

Association of left ventricular longitudinal myocardial function with subclinical right ventricular dysfunction in type 2 diabetes mellitus
por: Todo, Saki, et al.
Publicado: (2021)

Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis
por: Schulz, Kirsten, et al.
Publicado: (2015)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014)

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus
por: Bigagli, Elisabetta, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
por: Manrique, Camila, et al.
Publicado: (2016)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Ling, Ann Wan-Chin, et al.
Publicado: (2020)

Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
por: Jaenisch, Simone E., et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
por: Hausenloy, Derek J, et al.
Publicado: (2013)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
por: da Silva Júnior, Wellington Santana, et al.
Publicado: (2015)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Association of peripheral nerve conduction in diabetic neuropathy with subclinical left ventricular systolic dysfunction
por: Mochizuki, Yasuhide, et al.
Publicado: (2015)

Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis
por: Larrinaga, Gorka, et al.
Publicado: (2015)

Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats
por: Miyoshi, Toru, et al.
Publicado: (2014)

Plasma dipeptidyl-peptidase-4 activity is associated with left ventricular systolic function in patients with ST-segment elevation myocardial infarction
por: Li, Jing Wei, et al.
Publicado: (2017)

Evaluation of subclinical left ventricular dysfunction in overweight people with 3D speckle-tracking echocardiography
por: Doğduş, Mustafa, et al.
Publicado: (2019)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Esaki, Hiroki, et al.
Publicado: (2017)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
por: Nishida, Yayoi, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
por: Seong, Jong-Mi, et al.
Publicado: (2020)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

Insulin resistance and subclinical abnormalities of global and regional left ventricular function in patients with aortic valve sclerosis
por: Utsunomiya, Hiroto, et al.
Publicado: (2014)

The role of isovolumic acceleration in predicting subclinical right and left ventricular systolic dysfunction in patient with metabolic syndrome
por: Ertürk, Mehmet, et al.
Publicado: (2015)

Non alcoholic steatohepatitis is associated with subclinical impairment in left ventricular function measured by speckle tracking echocardiography
por: Baktır, Ahmet Oğuz, et al.
Publicado: (2015)

Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study
por: Nogueira, Katia Camarano, et al.
Publicado: (2014)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study
por: Liu, Xi, et al.
Publicado: (2018)

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
por: Chang, Chia-Yu, et al.
Publicado: (2017)

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
por: Dawwas, Ghadeer K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tsmc63edrn0oh720rqfjn6gd6u